Read the Finansavisen article (in Norwegian) here
Other News |
Press Releases
Open position as Head of Investor Relations and Communication
Ultimovacs is searching for Head of Investor Relations and Communication. For more information, please see here
Presentation at LifeSci Nordic Biotech Summit Tuesday 29 June 2021
CEO of Ultimovacs, Carlos de Sousa, will hold a company presentation at LifeSci Nordic Biotech Summit on Tuesday 29 June […]
Biostock article on Ultimovacs’ clinical data presented at ASCO
“This year’s virtual ASCO conference featured Ultimovacs’ recently released phase I data showing that cancer vaccine UV1 boosts the effects […]
ASCO data – HealthTalk interview with CMO Jens Bjørheim
See the whole interview here
Company update on Ultimovacs after the release of clinical data, has been published by Edison Investment Research
“Yesterday, Ultimovacs reported the first results from a Phase I trial of UV1 in advanced melanoma in combination with Keytruda. […]
Article in Dagens Medisin
“Det norske selskapet Ultimovacs står bak kreftvaksinen UV1. Over år ha selskapet forsket på vaksinen som er en peptid-basert vaksine, […]
Article in HealthTalk regarding the phase I data i MM
“Ultimovacs UV1 kreftvaksine i kombinasjon med immunterapien Keytruda har effekt på 60 prosent av pasientene med avansert føflekkreft. 60 prosent […]
BioStock article: “New data gives weight to Ultimovacs’s cancer vaccine”
“It would seem like Ultimovacs is on to something with its cancer vaccine UV1. New data from their phase I […]
Upcoming events
List of events where the Ultimovacs team will attend or present.